Growth factor receptor inhibitors

Docetaxel, pemetrexed, and an oral epidermal growth factor receptor inhibitor, erlotinib, are options for unresectable stage III or IV NSCLC patients with good performance status who progress during or after first-line therapy. [Pg.715]

Witta SE, Gemmill RM, Hirsch FR et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006 66 944-950. Walker F, Kato A, Gonez LJ et al. Activation of the Ras/mitogen-activated protein kinase pathway by kinase-defective epidermal growth factor receptors results in cell survival but not proliferation. Mol Cell Biol 1998 18 7192-7204. [Pg.124]

Elkind NB, Szentpetery Z, Apati A et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res... [Pg.125]

Strumberg D et al (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 965-972... [Pg.241]

Fox E et al (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavail-able pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28 5174-5181... [Pg.242]

Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006 55 57-70. [Pg.306]

Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006 107(6) 1207-1218. [Pg.228]

Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005 ll(15) 5472-5480. [Pg.229]

Johnson BE, Janne PA. Selecting patients for epidermal growth factor receptor inhibitor treatment A FISH story or a tale of mutations [see comment][comment]. J Clin Oncol. 2005 23 6813-6816. [Pg.458]

Erlotinib is an epidermal growth factor receptor inhibitor that inhibits intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor. It is indicated in the treatment of locally advanced or metastatic non-small-cell lung cancer after failure of at least 1 prior chemotherapy regimen. Erlotinib (Tarceva) is a human HER 1/EGER tyrosine kinase inhibitor with the following chemical formula A-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine. It is indicated in treatment of patients with locally advanced or metastatic non-small-cell lung cancer. [Pg.238]

Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005 11 7841-7850. [Pg.507]

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol... [Pg.556]

Heymach, J.V., Nilsson, M., Blumenschein, G., Papadimitrakopoulou, V., Herbst, R. Epidermal growth factor receptor inhibitors in development for the treatment of nonsmall cell lung cancer. Clinical Cancer Research an Official Journal of the American Association for Cancer Research 12(14 Pt 2), 4441s 4445s (2006)... [Pg.400]

Li X, Kamenecka TM, Cameron MD (2010) Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 38 1238-1245... [Pg.682]

Exposure of PC12 cells to 500 pM peroxynitrite activated extracellular-regulated kinases 1 and 2 and p38 within 5 min and this was followed by gradual decreases in activation over the next 25 min (JoPE etal. 2000). Activation of extracellular-regulated kinases 1 and 2 by peroxynitrite was mediated by activation of the epidermal growth factor receptor in a calcium/calmodulin-dependent kinase II- and sre family tyrosine kinase-dependent manner, as it was blocked by the selective epidermal growth factor receptor inhibitor AG1478, by... [Pg.519]

Ihle NT, Paine-Murrieta G, Berggren MI et al. (2005) The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4 1349-1357... [Pg.215]

Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor - associated cutaneous toxicities an evolving paradigm in chnical management. Oncologist. 2007 12 610-21. [Pg.417]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...